Developing a integrative clinical subtype and treatment model by identifying the common and differential mechanisms of cognitive dysfunction and depression.

Not Applicable

Conditions: Mental and behavioural disorders

Registration Number: KCT0007319

Lead Sponsor: Hallym University Medical Center- Chuncheon

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot yet recruiting

Sex: All

Target Recruitment: 500

Inclusion Criteria

1) Patients over 55 years of age.
2) A person who meets the diagnosis based on the following medical diagnosis.
- Diagnosis of Alzheimer's dementia and mild cognitive impairment: A patient diagnosed based on the diagnostic criteria of DSM-V and diagnostic impressions of CERAD-K (Korean Version of the Concortium to Establish a Registry of Alzheimer's Disease) evaluation.
- Depression Diagnosis: Patients diagnosed with major depressive disorder, minor depressive disorder, and subsymptomatic depressive disorder using MINI-K.
3) In the normal group, except for 2).
4) A person who can voluntarily decide to participate in this clinical trial, give written consent, and perform clinical procedures including filling out questionnaires. However, if the patient is unable to make a voluntary decision due to cognitive decline, his/her legal representative may decide to participate.

Exclusion Criteria

1) Persons with serious medical illnesses (heart failure, angina pectoris, myocardial infarction, arteriosclerosis, diabetes, inflammatory disease, malignancy, etc.) or psychiatric disease other than AD and MCI diagnosis.
2) Those diagnosed with bipolar or psychotic major depressive disorder.
3) Those with a history of seizures, brain surgery, organic brain disease or organic emotional disorder, and abnormal findings other than brain atrophy on brain MRI.
4) Those who are judged to have problems attaching EEG patches and near-infrared electrodes due to scalp deformities, inflammatory reactions, or other dermatological problems.
5) Those with a history of habitual drinking or drug abuse.
6) Patients with uncontrolled diabetes or hypertension.
7) Those who are judged to be inappropriate for this clinical trial by the investigator.
8) Patients with severe dementia (GDS score of 7 or higher or CDR score of 4 or higher).

Study & Design

Study Type: Observational Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
blood biomarker;Brain function: EEG (electroencephalography), fNIRS (functional near-infrared spectroscopy);neurocognitive function tests;psychological symptomatology assessment

Secondary Outcome Measures